Nektar Therapeutics(NKTR)
SAN FRANCISCO, CABiotechnology
Focus: Nektar Therapeutics is a public biotechnology company focused on discovering and developing small molecules and biologics across oncology, immunology, and other therapeutic areas. The company operates as a mid-cap biotech with a diversified pipeline spanning 50+ active trials.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
10+10 this month
Growing — net +10 jobs in 30d
14 jobs added vs 4 removed. Steady team buildout.
Should You Work at Nektar Therapeutics?
AI assessmentNektar offers exposure to a diverse pipeline and public company structure, but deteriorating financials and extremely high R&D burn present meaningful career risk.
Why Work Here
- Diverse pipeline with 50 active trials across oncology and immunology provides exposure to multiple therapeutic modalities and disease areas
- Public company status with $98M FY2025 revenue demonstrates sustainable operations and potential for equity upside
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Key Products
Growth
Multi-indication immuno-oncology asset in Phase 1/2 and Phase 2 development across solid tumors.
Help build intelligence for Nektar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.